Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY275585, Humalog
Insulin lispro 2 day reservoir in-use · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Insulin Lispro 2 Day | ACTIVE_COMPARATOR | - |
| Insulin Lispro 6 Day | EXPERIMENTAL | - |
| Insulin Aspart 6 Day | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Insulin lispro 2 day reservoir in-use | DRUG | Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period. |
| Insulin lispro 6 day reservoir in-use | DRUG | Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period. |
| Insulin aspart 6 day reservoir in-use | DRUG | Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period. |
Inclusion Criteria: * Diagnosed with type 1 diabetes (World Health Organization criteria) for at least 24 months. * Treated with continuous subcutaneous insulin infusion therapy for the previous 6 months. * Mean total daily insulin dose for 3 days prior to screening equal to or less than 46 units/d...
Insulin lispro 2 day reservoir in-use refers to a rapid-acting insulin lispro formulation evaluated for use in insulin pumps with a reservoir changed every two days. It is being developed by Eli Lilly and Company for type 1 diabetes mellitus. The formulation is designed to provide mealtime and continuous subcutaneous insulin delivery in pump therapy.
Insulin lispro 2 day reservoir in-use is used for glycemic control in people with type 1 diabetes mellitus who use insulin pumps. It delivers rapid-acting insulin through a pump reservoir intended for two-day use. The Phase 3 trial enrolled 132 participants aged 13 years and older with type 1 diabetes.
Insulin lispro 2 day reservoir in-use targets the insulin receptor, INSR, as an agonist. Binding to INSR activates downstream signaling that promotes glucose uptake into muscle and fat tissue and suppresses hepatic glucose output. This receptor-mediated action underlies its glucose-lowering effect in type 1 diabetes.
Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY, is the developer of insulin lispro 2 day reservoir in-use. Lilly is the manufacturer of the insulin lispro molecule and conducted the clinical development program for this pump-use formulation in type 1 diabetes.
Insulin lispro 2 day reservoir in-use has been studied in Phase 3 clinical development. It is an investigational product and is not described as FDA approved. One Phase 3 trial has been completed, and no trials are currently listed as active for this formulation.
The Phase 3 trial NCT01109316, titled Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use, evaluated insulin lispro 2 day reservoir in-use in type 1 diabetes. The completed study enrolled 132 participants in the United States, used an active-controlled design, and included participants aged 13 years and older.